Dashboard
Manage Tickers

EOLS Evolus, Inc.

Nasdaq evolus.com


$ 7.09 $ 0.49 (7.47 %)    

Monday, 10-Nov-2025 16:46:50 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.82 $ 4.38 (0.71 %)
DIA $ 473.95 $ 1.94 (0.41 %)
SPY $ 681.69 $ 4.15 (0.61 %)
TLT $ 89.46 $ 0.06 (0.07 %)
GLD $ 380.15 $ 2.40 (0.64 %)
$ 7.05
$ 6.65
$ 6.52 x 40
$ 7.35 x 500
$ 6.57 - $ 7.26
$ 5.71 - $ 17.12
3,320,231
na
456.98M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 03-04-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 07-31-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-07-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-08-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-03-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 03-20-2019 12-31-2018 10-K
29 11-05-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
11/06/2025 12:05:55

correction-evolus-q3-adj-eps-011-beats-017-estimate-sales-68967m-beat-67449m-estimate
CORRECTION: Evolus Q3 Adj. EPS $(0.11) Bea...
11/05/2025 23:42:53

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36....

evolus-affirms-fy2025-sales-guidance-of-295000m-305000m-vs-295999m-est
Evolus Affirms FY2025 Sales Guidance of $2...
11/05/2025 21:21:14

Evolus (NASDAQ:EOLS) affirms FY2025 sales outlook from $295.000 million-$305.000 million to $295.000 million-$305.000 million v...

evolus-q3-eps-024-beats-026-estimate-sales-68967m-beat-67449m-estimate
Evolus Q3 EPS $(0.24) Beats $(0.26) Estima...
11/05/2025 21:20:44

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 8.7...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

watching-evolus-hearing-zacks-under-10-newsletter-mentions-stock-as-a-buy
Watching Evolus; Hearing Zacks Under $10 N...
11/04/2025 14:55:09

btig-reiterates-buy-on-evolus-maintains-18-price-target
BTIG Reiterates Buy on Evolus, Maintains $...
09/08/2025 15:49:01

BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.

evolus-appoints-tatjana-mitchell-as-cfo-effective-september-8-2025
Evolus Appoints Tatjana Mitchell As CFO, E...
09/08/2025 12:32:50

evolus-announces-us-study-of-evolysse-sculpt-met-primary-endpoint-of-non-inferiority-and-showed-statistical-superiority-to-restylane-lyft
Evolus Announces US Study Of Evolysse Scul...
08/25/2025 12:08:41

evolus-submits-final-fda-pma-module-for-evolysse-sculpt-injectable-ha-gel
Evolus Submits Final FDA PMA Module For Ev...
08/20/2025 12:04:13

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, to...

btig-maintains-buy-on-evolus-lowers-price-target-to-18
BTIG Maintains Buy on Evolus, Lowers Price...
08/06/2025 18:02:10

BTIG analyst Sam Eiber maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $21 to $18.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 17:06:59

needham-downgrades-evolus-to-hold-maintains-price-target-to-22
Needham Downgrades Evolus to Hold, Maintai...
08/06/2025 12:34:49

Needham analyst Serge Belanger downgrades Evolus (NASDAQ:EOLS) from Buy to Hold and maintains the price target from $22 to $22.

super-micro-computer-posts-downbeat-q4-results-joins-personalis-snap-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Super Micro Computer Posts Downbeat Q4 Res...
08/06/2025 12:11:55

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

hc-wainwright--co-maintains-buy-on-evolus-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on Evolu...
08/06/2025 11:19:24

HC Wainwright & Co. analyst Douglas Tsao maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $27 ...

why-astera-labs-shares-are-trading-higher-by-over-17-here-are-20-stocks-moving-premarket
Why Astera Labs Shares Are Trading Higher ...
08/06/2025 09:35:31

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/05/2025 21:07:20

evolus-lowers-fy2025-sales-guidance-from-345000m-355000m-to-295000m-305000m-vs-348308m-est
Evolus Lowers FY2025 Sales Guidance from $...
08/05/2025 20:19:00

Evolus (NASDAQ:EOLS) lowers FY2025 sales outlook from $345.000 million-$355.000 million to $295.000 million-$305.000 million vs...

evolus-q2-adj-eps-023-misses-010-estimate-sales-69387m-miss-82182m-estimate
Evolus Q2 Adj. EPS $(0.23) Misses $(0.10) ...
08/05/2025 20:11:26

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.10) by 1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION